Cargando…
Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries
BACKGROUND: Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC) worldwide. In Europe, people who inject drugs (PWID) represent the majority of HCV infections, but are often excluded from treatment. The aim of this study was...
Autores principales: | Maticic, Mojca, Zorman, Jerneja Videcnik, Gregorcic, Sergeja, Schatz, Eberhard, Lazarus, Jeffrey V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509821/ https://www.ncbi.nlm.nih.gov/pubmed/31072401 http://dx.doi.org/10.1186/s12954-019-0303-9 |
Ejemplares similares
-
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries
por: Maticic, Mojca, et al.
Publicado: (2014) -
A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region
por: Lazarus, Jeffrey V, et al.
Publicado: (2014) -
A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia
por: Maticic, Mojca
Publicado: (2014) -
The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs
por: Schatz, Eberhard, et al.
Publicado: (2016) -
Hep‐CORE: a cross‐sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017
por: Lazarus, Jeffrey V, et al.
Publicado: (2018)